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Actinic keratosis (AK) lesions are surrounded by field 
cancerization (areas of subclinical, non-visible sun da-
mage). Existing AK grading tools rely on AK counts, 
which are not reproducible. An Actinic Keratosis Field 
Assessment Scale (AK-FAS) for grading the severity 
of AK/field was developed. Standardized photographs 
of patients representing the full range of AK severity 
were collected. Six investigators independently rated 
each photograph according to 3 criteria: AK area (total 
skin area affected by AK lesions), hyperkeratosis and 
sun damage. Inter-rater reproducibility was good for 
all 3 criteria. Validation of the AK-FAS showed good 
reproducibility for AK area and hyperkeratosis, even 
for dermatologists untrained on use of the scale. In 
conclusion, the AK-FAS is objective, easy to use and 
implement, and reproducible. It incorporates assess-
ment of the entire field affected by AK instead of rely-
ing on lesion counts. Use of the AK-FAS may standar-
dize AK diagnosis, making it relevant to routine clinical 
practice.
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Actinic keratosis (AK) is a prevalent disease typically affecting areas of sun-exposed skin (1). Estimates 
of AK prevalence range between 6 and 60% (depending 
on skin phototype, geographical location, age, and other 
predisposing factors), and prevalence appears to be 
increasing. Therefore, AK presents a substantial soci-
oeconomic burden, the weight of which will inevitably 
increase with an ageing population (1, 2).
Surrounding visible AK lesions are areas of subclini-
cal, non-visible sun damage prone to the development of 
clinically visible or recurrent AK lesions and sun-related 
skin cancers. This is known as field cancerization (3). 
In this context, AK can be considered a chronic disease. 
Treating field cancerization is instrumental in reducing 
rates of AK recurrence, thus reducing the burden of AK 
(4–6). Consequently, recent guidelines advocate treating 
field cancerization instead of only individual, visible AK 
lesions (4, 7, 8). 
Key barriers to shifting the treatment paradigm in 
accordance with current guidelines are the lack of a 
standardized definition of field cancerization and of a 
reproducible assessment scale for grading the whole area 
affected by AK. Instead, existing AK grading tools, such 
as the Olsen clinical classification scale and the Roewert-
Huber histological classification scale, assess individual, 
isolated AK lesions (9–11) and current guidelines rely on 
lesion counts, which are not reproducible even among 
experts, to assess AK severity (4, 7, 8, 12–14). A recent 
study assessing the correlation between clinical and 
histological assessment of single AK lesions showed 
that only approximately half of the investigated lesions 
matched in terms of grading severity on the Olsen and 
Roewert-Huber scales, thus supporting the notion that 
clinical classification of single lesions does not accurately 
assess the underlying histology (15).
The need for a reproducible assessment scale to guide 
the identification and diagnosis of AK has been highligh-
ted by therapy experts. Such a scale could help to make 
appropriate treatment decisions and to quantitatively 
assess response to treatment. The purpose of this study 
was to develop, test and validate an Actinic Keratosis 
Field Assessment Scale (AK-FAS) based on photogra-
phic clinical cases. 
METHODS
Development of Actinic Keratosis Field Assessment Scale (AK-FAS)
Six investigators met on 15 July 2016 to develop and test the 
AK-FAS. 
The initial draft of the AK-FAS was based on a combination of 
Olsen criteria for AK (9) and an assessment scale developed by 
the lead investigator, with the following definitions:
• Grade 0 = no AKs on sun-damaged skin.
• Grade I = AK on surrounding skin that is < 25% sun damaged.
• Grade II = multiple flat AKs on surrounding skin that is 25–74% 
sun damaged.
• Grade III = multiple AKs (of visible thickness) on surrounding 
skin that is >75% sun damaged.
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This draft was discussed by the investigators, who identified both 
the limitations of the scale and potential solutions to overcome 
these limitations. They found that the proposed definitions were 
difficult to interpret consistently as many clinical presentations 
could fall between grades.
A second version of the scale was drafted to overcome these limi-
tations. In this version, the assessment criteria were separated into 
3 criteria that could be assessed individually: AK area, hyperkera-
tosis, and sun damage. AK area is the most important criterion in 
the scale and the key differentiator from previous tools. Instead of 
counting AK lesions, all visible alterations identified as AK lesions 
are assessed, with the AK area defined as the combined total area of 
the skin affected by AK lesions, given as a percentage of the total 
skin area assessed (i.e. whole face or scalp), which also includes 
sub-clinical, non-visible lesions. AK area was graded on a 5-point 
scale, depending on the percentage range of skin area covered by 
AK lesions. This should increase reproducibility compared with 
lesion counts (Table I). Hyperkeratosis and sun damage in the area 
were then marked as either present or absent. Preliminary testing 
of this scale, carried out in 12 photographic cases (8 faces and 4 
scalps), highlighted that it was limited by differing interpretations 
of hyperkeratosis presence or absence, which led to discrepancies 
in clinical assessment. In addition, sun damage had little value as 
a category as it was always marked as present.
Therefore, in producing the final scale, the grading for AK area 
was retained and definitions of hyperkeratosis and sun damage 
presence or absence in terms of their severity were added. Signs 
considered during the evaluation of sun damage included: ery-
thema, telangiectasia, inflammation, atrophy and pigmentation 
disorders. Sun damage was defined as moderate or severe if it 
would lead the investigator to follow up the patient more frequently 
vs none/mild sun damage, according to the investigator’s own 
judgement. The final AK-FAS is presented in Table I. Photographs 
representing AK grades I-IV and hyperkeratosis presence/absence, 
are shown in Fig. 1 and Fig S11, respectively.
Validation using selected photographs 
Photographs of 108 patients with AK seen in clinical practice by 
the investigators were provided. All patients provided written 
permission to use their photographs for research purposes. The 
photography was standardized, with photographs taken using a 
digital camera, against a black, blue or white background at a 
resolution >3 megapixels. Photographs were taken of the first 2 
AK patients seen each day by each of the 8 investigators during 
a 2–3-week period (May–July 2016) and included patients with 
a range of disease severity on the face or face and scalp. For the 
face, 3 photographs were taken: front profile and right and left 
profiles (at an angle of 45° or 90°). One photograph of the scalp 
was taken in bald patients. To ensure good quality, the first 2 sets 
of patient photographs taken by each investigator were assessed 
by the same reviewer within 2 days of the photographs being ta-
ken and feedback was given on their suitability. For standardized 
presentation, photographs of the face were cropped between the 
top of the head and the jaw-line, and those of the scalp between 
the top of the scalp and the eyebrows. The forehead was consi-
dered as part of the face and was delineated from the scalp using 
a demarcation line to ensure that all investigators were assessing 
exactly the same area when applying the AK-FAS. The entire area 
shown in the photograph (face or scalp) should be considered 
when applying the scale.
Once all cases had been collected, each investigator selected 
the best clinical cases (in terms of image quality) based on their 
expert judgement, ensuring equal spread across AK severity. All 
collected cases were submitted to a central server. The pictures 
considered by the investigators as the best cases (n = 96) were used 
for evaluation and validation of the final AK-FAS; the remaining 
cases (n = 12) were used during the development of the AK-FAS 
for preliminary testing.
Testing of Actinic Keratosis Field Assessment Scale (AK-FAS)
The final AK-FAS was tested separately on face and scalp areas 
(on 66 and 30 photographic cases, respectively). Assessment for 
each area was repeated (with at least 1 h between assessments) 
to allow evaluation of inter- and intra-rater agreement. The order 
of the photographic cases was randomly changed in the repeat 
assessment, in order to minimize grading by memory. The in-
vestigators had not previously seen any of the cases provided 
by their colleagues and were not allowed to confer during the 
assessment. Assessment took place using a keypad device that 
allowed each investigator to grade each case anonymously. For the 
first assessment session (face) investigators had 15 s (i.e. 45 s in 
total) to grade each category in the scale (AK area, hyperkeratosis 
and sun damage) with a 10-s gap (blank screen) in between. For 
subsequent sessions (repeat face, scalp and repeat scalp) there 
was no minimum time to select a grade, moving between cases 
as soon as assessment on all categories had been completed by all 
investigators. Conditions (lightning and distance from the screen) 
were standardized and recorded to ensure they were reproducible 
between sessions. 
Validation of Actinic Keratosis Field Assessment Scale (AK-FAS)
The same process described above was subsequently repeated 
(also face-to-face) by 2 untrained investigators who were not 
involved in the development of the AK-FAS. They assessed the 
same photographic cases under the same conditions. Both received 
only a written description of the final AK-FAS with no training 
(Table I). Only brief training on the use of the keypad devices 
used in the anonymous grading of cases was provided, practicing 
on the same 12 cases used for preliminary testing during the 
development process.
Statistical methods
Kappa (κ) is commonly used in the medical literature to measure 
inter-observer variation. The calculation is based on the difference 
between how much agreement is actually present (“observed” 
agreement) compared with how much agreement would be ex-
pected to be present by chance alone (“expected” agreement) 
(17). Cohen’s κ was calculated to evaluate inter- and intra-rater 
agreement in the grading of AK using the newly developed AK-
FAS for the following situations: face and scalp combined; face 
only; scalp only. Inter- and intra-rater agreement was assessed for 
the 6 investigators involved in development of the scale and the 2 
investigators involved in validation of the scale.
Table I. Final Actinic Keratosis Field Assessment Scale (AK-FAS)
AK Grade 0 I II III IV
AK area (% area 
covered by AK)a
0 < 10 10–25 > 25–50 > 50
Hyperkeratosis
severity +: ≥ 1 AK(s) with grade II or III and hyperkeratosisb ≥ 5 mm 
in diameter are present in the area
–: no hyperkeratosis or grade I hyperkeratosisb is present
Sun damage 
severity 
+: moderate or severe sun damage, leading to more frequent 
patient follow-up
–: none or mild sun damage
Signs considered in the evaluation: erythema, telangiectasia, 
inflammation, atrophy and pigmentation disorders
aIn either face or scalp. bAs defined by the Primary Care Dermatology Society (16).
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2710
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The κ statistic was selected because the variable of interest was 
binary for hyperkeratosis and sun damage, and could be weighted 
for categorical AK (Grades 0 to 4). κ is a measure of difference 
standardized to fit on a –1 to 1 scale, where 1 is perfect agreement, 
0 is exactly what would be expected by chance, and negative va-
lues indicate agreement less than chance (i.e. potential systematic 
disagreement between the raters). The interpretation of agreement 
adopted here is: less than chance agreement (κ < 0), slight agre-
ement (κ = 0.01–0.20), fair agreement (κ = 0.21–0.40), moderate 
agreement (κ = 0.41–0.60), substantial agreement (κ = 0.61–0.80), 
and almost perfect agreement (κ = 0.81–0.99) (18). The interpreta-
tion of reproducibility adopted is: marginal (κ = 0.00–0.40), good 
(κ = 0.40–0.75) and excellent (κ  > 0.75) (19).
RESULTS
Validation of Actinic Keratosis Field Assessment Scale 
(AK-FAS) by investigators
Inter-rater reproducibility. There was substantial agre-
ement for 2 criteria (AK area and hyperkeratosis) and 
moderate agreement for the third criteria (sun damage), 
indicating good reproducibility between the 6 investi-
gators who developed and tested the scale. For face and 
scalp combined, the inter-rater κ scores were 0.69, 0.71 
and 0.51, respectively (Table II). Similar results were 
Fig. 1. Actinic keratosis (AK) grade. (A) Grade I: < 10% area covered by AK; (B) Grade II: 10–25% area covered by AK; (C) Grade III: >25–50% 
area covered by AK; (D) Grade IV: > 50% area covered by AK.
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obtained in the evaluation of the face and scalp separa-
tely (Table II).
Intra-rater reproducibility. Intra-rater reproducibility 
was good for all criteria (AK area, hyperkeratosis and 
sun damage). Corresponding κ values were in the sub-
stantial agreement range for all investigators for AK area, 
almost perfect or substantial agreement range for all but 
one of the investigators for hyperkeratosis and moderate 
agreement range for the majority of the investigators for 
sun damage.
Validation of the Actinic Keratosis Field Assessment 
Scale (AK-FAS) by untrained investigators
The κ values for the 2 untrained investigators not invol-
ved in the development of the scale were lower than, but 
in alignment with, those obtained during the original tes-
ting of the scale with κ scores of 0.59, 0.54 and 0.38, re-
spectively, for AK area, hyperkeratosis and sun damage, 
indicating moderate agreement (good reproducibility) for 
AK area and hyperkeratosis, and fair agreement for sun 
damage (Table II). Similar results were obtained for the 
face and scalp analysed separately (Table II).
DISCUSSION
The results of this study demonstrate that the newly 
developed AK-FAS for grading AK severity is objective 
and easy to use. Reproducibility (both inter- and intra-
rater) is good, particularly for 2 criteria (AK area and 
hyperkeratosis). To our knowledge, the AK-FAS is the 
only scale considering the extent of skin area affected by 
AK, rather than lesion counts, which may not describe 
the extent of the disease and are difficult to reproduce 
consistently. Considering the extent of the skin area af-
fected by AK (both visible and subclinical lesions) will 
make the AK-FAS highly relevant for clinical practice.
Despite the relatively small number of investigators 
involved in the development, testing and validation of 
the AK-FAS, it was used in over 1,500 gradings (as 
each of the 8 investigators graded each photograph 
twice) and the reproducibility results were highly 
significant. Reproducibility was slightly lower when 
the analysis was carried out by only the 2 untrained 
investigators responsible for scale validation, who were 
not involved in the development of the scale. This is 
to be expected, as the 6 investigators who developed 
the scale had lengthy discussions on how to define and 
use the scale, including a pilot voting session where 
they discussed their choices of grading, hence calibra-
ting their grading against each other. In contrast, the 2 
untrained investigators validating the scale were only 
provided with a written description of the scale, and 
had no opportunity for calibrating against each other 
or with the other investigators. 
Interestingly, an assessment of Psoriasis Area and 
Severity Index (PASI) scoring among patients and phy-
sicians with first exposure to PASI showed that use of a 
simple online training video improved scoring accuracy 
for both physicians and patients compared with scoring 
accuracy before training, using the scores of PASI-expe-
rienced physicians as the standard for comparison (20). 
This suggests that some simple training on AK-FAS use, 
although not essential, would benefit standardization. 
Previously, the Olsen scale, which grades severity/
thickness of individual AK lesions in isolation, has been 
the only existing clinical scale used to assess AK severity 
(9). Consequently, the Olsen scale combined with lesion 
counts, often within a relatively small area, has been 
employed in clinical trials of field therapies to assess 
extent of disease severity and treatment effectiveness (9, 
21–23). However, individual lesion counts are associa-
ted with poor reproducibility, with different healthcare 
professionals, including those with extensive experience, 
likely to calculate different lesion counts when assessing 
the same patient (12–14). Moreover, reduction in size of 
lesions is not accounted for as an effect of a treatment 
and may result in a false-negative effect. Therefore, 
while assessment of disease severity based on the Olsen 
scale and lesion counts is practical, it is unreliable and 
inconsistent for routine application.
Current treatment algorithms and guidelines rely on 
the Olsen scale and/or lesion counts for assessing disease 
extent and providing treatment recommendations (4, 8, 
24), and such guidelines are therefore also limited for 
clinical practice. In clinical practice, dermatologists need 
to assess the severity of AK in the entire area affected 
in order to make a fully informed decision on optimum 
disease management options. The AK-FAS reported 
here is the only scale to grade severity of AK taking 
into consideration the whole area affected by the disease 
(entire face or scalp). 
Table II. Agreement between the 6 investigators who developed 
and tested the Actinic Keratosis Field Assessment Scale (AK-FAS) 
and the 2 untrained investigators who validated the AK-FAS 
Investigators who 
developed the scale (n = 6)
Untrained investigators 
(n = 2)
Agree-
ment 
%
Expected 
agree -
ment 
% κ SE
Agree-
ment 
%
Expected 
agree -
ment 
% κ SE
Face+scalp
AK grade 93.35 78.00 0.69 0.03 87.89 69.80 0.59 0.04
Hyperkeratosis 86.19 52.02 0.71 0.04 77.08 49.35 0.54 0.06
Sun damage 93.04 85.81 0.51 0.04 90.10 84.06 0.38 0.06
Face
AK grade 94.19 82.96 0.65 0.04 87.88 75.83 0.49 0.05
Hyperkeratosis 85.46 56.47 0.66 0.05 74.24 49.54 0.48 0.08
Sun damage 90.66 81.55 0.49 0.04 87.12 78.93 0.38 0.07
Scalp
AK grade 88.64 64.37 0.68 0.05 87.92 65.74 0.64 0.09
Hyperkeratosis 87.78 51.04 0.75 0.07 83.33 50.00 0.66 0.12
Sun damage 98.32 96.15 0.56 0.06 96.67 96.67 0.00 0.00
AK: actinic keratosis; SE: standard error.
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A hyperkeratosis grading was included in the AK-FAS. 
Experts believe that thick AK lesions represent a more 
advanced disease stage than thin AKs and are therefore 
more important to treat (13, 25–29). However, recent 
studies testing a correlation between clinical thickness 
of AK lesions and dysplasia for the first time, suggest 
that this may not always be the case (15, 26). Regardless 
of whether or not hyperkeratosis is indicative of disease 
progression, most topical treatments for AK are not 
indicated for use on hyperkeratotic lesions. Therefore, a 
hyperkeratosis grading is relevant to inform the decision-
making process (8). 
Sun damage beyond visible AK lesions was included 
in the AK-FAS as decisions on patient management may 
be influenced by the severity of sun damage. However, 
the significance of sun damage is not fully known, as AK 
lesions can exist on skin with little sign of additional sun 
damage. Conversely, skin with severe sun damage (e.g. 
solar elastosis) can be clear of AK lesions. Interestingly, 
reproducibility for assessment of sun damage was lower 
than for AK area and hyperkeratosis, highlighting that 
a clear definition of sun damage in the context of AK is 
lacking, as is a clear understanding of its implications. 
Both of these areas would be of interest for future in-
vestigation.
The AK-FAS has been developed, tested and validated 
through the use of photographic scoring. A photographic 
scale allows the inclusion of patients and assessment by 
expert dermatologists encompassing several European 
countries, which would be extremely difficult to achieve 
in real-life patients. This ensures that the scale is relevant 
and applicable at a pan-European level and facilitates 
communication, dissemination and implementation of 
the AK-FAS. In addition, a photographic scale is very 
well suited for telemedicine and telediagnosis. This is a 
growing practice that increases patient access to specia-
lists, reduces waiting times and facilitates communica-
tion among healthcare professionals; it is particularly 
well-suited for dermatology due to the visual nature of 
the discipline (30). It would be of interest, however, to 
extend testing and validation of the AK-FAS to patients 
in the clinic, as palpation of the skin is an important 
tool in the assessment of AK. Some AKs may only be 
detectable through palpation, which could lead to dis-
crepancies between the photographic scoring and patient 
assessment in the clinic. Future research should test this 
AK-FAS tool in real patients in order to assess if there 
is a significant discrepancy compared with photographic 
assessment and to establish potential corrections to the 
photographic scale if this is the case. 
In conclusion, the AK-FAS is an objective and easy 
to learn and implement assessment of AK that is re-
producible and relevant to routine clinical practice, 
incorporating assessment of the entire field affected by 
AK rather than individual lesions. It is likely to lead to 
a more standardized approach than current assessment 
scales when diagnosing AK and considering treatment 
options, which is crucial in AK given the chronicity of 
the condition. This will potentially increase the cost-
effectiveness of AK disease management by maximizing 
the chances of selecting the most appropriate treatment 
from the outset, as well as providing an objective method 
to assess treatment response. 
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